193 related articles for article (PubMed ID: 32800674)
1. The role, efficacy and outcome measures for teriparatide use in the management of medication-related osteonecrosis of the jaw.
Anabtawi M; Tweedale H; Mahmood H
Int J Oral Maxillofac Surg; 2021 Apr; 50(4):501-510. PubMed ID: 32800674
[TBL] [Abstract][Full Text] [Related]
2. A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration.
Ohbayashi Y; Iwasaki A; Nakai F; Mashiba T; Miyake M
Osteoporos Int; 2020 Mar; 31(3):577-585. PubMed ID: 31768589
[TBL] [Abstract][Full Text] [Related]
3. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.
Dos Santos Ferreira L; Abreu LG; Calderipe CB; Martins MD; Schuch LF; Vasconcelos ACU
Osteoporos Int; 2021 Dec; 32(12):2449-2459. PubMed ID: 34331067
[TBL] [Abstract][Full Text] [Related]
4. Effective ancillary role and long-term course of daily or weekly teriparatide treatment on refractory medication-related osteonecrosis of the jaw: a clinical case series.
Yoshiga D; Yoshioka I; Habu M; Sasaguri M; Tominaga K
Br J Oral Maxillofac Surg; 2022 Jun; 60(5):604-609. PubMed ID: 34996629
[TBL] [Abstract][Full Text] [Related]
5. Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw.
Kim KM; Park W; Oh SY; Kim HJ; Nam W; Lim SK; Rhee Y; Cha IH
Osteoporos Int; 2014 May; 25(5):1625-32. PubMed ID: 24554340
[TBL] [Abstract][Full Text] [Related]
6. Teriparatide for the Treatment of Medication-Related Osteonecrosis of the Jaw.
Chopra K; Malhan N
Am J Ther; 2020 Jun; 28(4):e469-e477. PubMed ID: 32618592
[TBL] [Abstract][Full Text] [Related]
7. The effects of different doses of teriparatide on bisphosphonate-related osteonecrosis of the jaw in mice.
Yu W; Su J
Oral Dis; 2020 Apr; 26(3):609-620. PubMed ID: 31903673
[TBL] [Abstract][Full Text] [Related]
8. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.
Sim IW; Borromeo GL; Tsao C; Hardiman R; Hofman MS; Papatziamos Hjelle C; Siddique M; Cook GJR; Seymour JF; Ebeling PR
J Clin Oncol; 2020 Sep; 38(26):2971-2980. PubMed ID: 32614699
[TBL] [Abstract][Full Text] [Related]
9. Management of bisphosphonate-related osteonecrosis of the jaw using teriparatide treatment: A systematic review.
Varoneckas A; Gelažius R; Pliavga V; Leketas M; Kubilius R; Varoneckaitė M
Stomatologija; 2022; 24(3):63-70. PubMed ID: 37140255
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): A multicenter retrospective analysis in Japan.
Morishita K; Yamada SI; Kawakita A; Hashidume M; Tachibana A; Takeuchi N; Ohbayashi Y; Kanno T; Yoshiga D; Narai T; Sasaki N; Shinohara H; Uzawa N; Miyake M; Tominaga K; Kodani I; Umeda M; Kurita H
J Orthop Sci; 2020 Nov; 25(6):1079-1083. PubMed ID: 32111549
[TBL] [Abstract][Full Text] [Related]
11. Weekly teriparatide injections successfully treated advanced bisphosphonate-related osteonecrosis of the jaws.
Yoshiga D; Yamashita Y; Nakamichi I; Tanaka T; Yamauchi K; Yamamoto N; Nogami S; Kaneuji T; Mitsugi S; Sakurai T; Kiyomiya H; Tominaga K; Morimoto Y; Takahashi T
Osteoporos Int; 2013 Aug; 24(8):2365-9. PubMed ID: 23371327
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Osteonecrosis of the Jaw.
Yamachika E; Matsubara M; Ikeda A; Matsumura T; Moritani N; Iida S
J Craniofac Surg; 2015 Oct; 26(7):e575-7. PubMed ID: 26468825
[TBL] [Abstract][Full Text] [Related]
13. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
14. [The recombinant human parathyroid hormone, teriparatide as an alternative remedy for the medication-related osteonecrosis of the jaw].
Gera I; Szücs N
Orv Hetil; 2023 Sep; 164(36):1406-1415. PubMed ID: 37695713
[TBL] [Abstract][Full Text] [Related]
15. Short-Term Teriparatide and Recombinant Human Bone Morphogenetic Protein-2 for Regenerative Approach to Medication-Related Osteonecrosis of the Jaw: A Preliminary Study.
Jung J; Yoo HY; Kim GT; Lee JW; Lee YA; Kim DY; Kwon YD
J Bone Miner Res; 2017 Dec; 32(12):2445-2452. PubMed ID: 28815779
[TBL] [Abstract][Full Text] [Related]
16. Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings.
Kakehashi H; Ando T; Minamizato T; Nakatani Y; Kawasaki T; Ikeda H; Kuroshima S; Kawakami A; Asahina I
Int J Oral Maxillofac Surg; 2015 Dec; 44(12):1558-64. PubMed ID: 26304604
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Medication-Related Osteonecrosis of the Jaw Around the Dental Implant With a Once-Weekly Teriparatide: A Case Report and Literature Review.
Kim JY; Park JH; Jung HD; Jung YS
J Oral Implantol; 2019 Oct; 45(5):403-407. PubMed ID: 31429640
[TBL] [Abstract][Full Text] [Related]
18. Management of medication-related osteonecrosis of jaw: Comparison between icariin and teriparatide in a rat model.
Liu J; Mattheos N; Deng C; Su C; Wang Z; Luo N; Tang H
J Periodontol; 2021 Jan; 92(1):149-158. PubMed ID: 32281098
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy.
Lee JJ; Cheng SJ; Jeng JH; Chiang CP; Lau HP; Kok SH
Head Neck; 2011 Sep; 33(9):1366-71. PubMed ID: 20310042
[TBL] [Abstract][Full Text] [Related]
20. Teriparatide therapy for bisphosphonate-related osteonecrosis of the jaw: a case report and narrative review.
Thumbigere-Math V; Gopalakrishnan R; Michalowicz BS
Northwest Dent; 2013; 92(1):12-8. PubMed ID: 23516715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
